PreAsthmaControl (PAC)

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: Pulmicort (budesonide) pMDI

Study type: Interventional

Funder types: Industry

Identifiers

NCT00234390

SD-004-0299

Details and patient eligibility

About

The purpose of this study is to investigate the ability of budesonide, given during episodes of troublesome lung symptoms to reduce further symptoms in infants and young children at risk of developing asthma

Sex: All

Ages: Under 6 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children of asthmatic mothers form the COPSAC birth cohort study

Exclusion criteria

• Children born more than 4 weeks preterm
• children with other systemic illness that atopy/allergy
• Children requiring mechanical ventilation at any time since birth.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind